Recent Articles
16Therapeutics Company Octant Secures $80 Million In Series B Funding - Pulse 2.0
Therapeutics Company Octant Secures $80 Million In Series B Funding Pulse 2.0
4/27/2022
Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson Sonsini
Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb Wilson Sons
4/22/2022
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership - Fierce Biotech
4/21/2022
Who is Chris Dixon? - Fortune
4/21/2022
Octant Scores $80M in Series B Funds, Partnership with BMS - BioSpace
4/21/2022
Catalio Capital Management Leads $80M Series B in Octant - citybiz
Catalio Capital Management Leads $80M Series B in Octant citybiz
4/21/2022
BMS joins Octant’s $80M financing and signs on as a drug discovery partner - MedCity News
BMS joins Octant’s $80M financing and signs on as a drug discovery partner MedCity News
4/21/2022
The VC who helped spin up Andreessen Horowitz's bio fund just raised $50 million for a third solo fund - Business Insider
The VC who helped spin up Andreessen Horowitz's bio fund just raised $50 million for a third solo fund Busi
6/3/2021
Genentech taps Stanford University spinout for AI drug discovery partnership - Fierce Biotech
10/19/2020
Embracing the Intersections of Innovation: Our Investment in Nautilus Biotechnology - Madrona
5/20/2020
Venture-Capital Investors Share Their Healthcare Predictions for 2020 - Business Insider
Venture-Capital Investors Share Their Healthcare Predictions for 2020 Business Insider
12/19/2019
Dog cancer treatment startup raises $5 million from Andreessen Horowitz and others - TechCrunch
1/23/2019
TwoXAR announces Series A in quest to collapse drug discovery timelines - MIT Sloan
3/21/2018
Artificial intelligence firm twoXAR raises $10M for partnering drive - Fierce Biotech
3/19/2018
Andreessen Horowitz Is Digging Deeper Into Biotech - BuzzFeed News
Andreessen Horowitz Is Digging Deeper Into Biotech BuzzFeed News
6/21/2017
Andreessen Horowitz Invests in Freenome Through New Bio Fund - Business Insider
6/9/2016
Investment Signals
10Octant secured a partnership with Bristol Myers Squibb, a major pharmaceutical company, validating its technology and market relevance.
Octant raised $80 million in Series B funding, indicating strong investor confidence in the company's biotech capabilities and commercial potential.
Andreessen Horowitz is increasing its focus and investment activity in the biotech sector, signaling confidence in the space's long-term potential.
VCs are making healthcare-focused predictions for 2020, indicating active investor focus on the healthtech sector.
Large pharma (BMS) is actively investing in and partnering with biotech companies for drug discovery capabilities, suggesting a thesis around outsourced discovery platforms.
BMS participates in Octant's $80M financing round and establishes a strategic drug discovery partnership, signaling confidence in the company's platform.
The track record and fundraising success of this VC suggests sustained investor confidence in biotech as a viable investment thesis, particularly for experienced operators launching new funds.
A prominent VC investor with significant experience from a16z's bio fund has successfully raised $50 million for their third independent fund, signaling continued confidence in biotech investment opportunities.
Octant, a therapeutics company, successfully raised $80 million in Series B funding, indicating investor confidence in their drug development platform.
Catalio Capital Management led an $80M Series B funding round for Octant, indicating significant capital deployment in fintech sector.